These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 34944794)

  • 1. Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance.
    Greene MK; Johnston MC; Scott CJ
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming multidrug resistance with nanomedicines.
    Ganoth A; Merimi KC; Peer D
    Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress.
    Ortíz R; Quiñonero F; García-Pinel B; Fuel M; Mesas C; Cabeza L; Melguizo C; Prados J
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33923200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients.
    Bhattacharjee S; Brayden DJ
    Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
    Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
    Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
    Tekchandani P; Kurmi BD; Paliwal SR
    Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
    Xue X; Liang XJ
    Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Polymeric Nanomedicines for Oncology: Perspectives and Future Directions.
    Fletcher NL; Kempe K; Thurecht KJ
    Macromol Rapid Commun; 2020 Sep; 41(18):e2000319. PubMed ID: 32767396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines for combating multidrug resistance of cancer.
    Zhu YX; Jia HR; Duan QY; Wu FG
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1715. PubMed ID: 33860622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines for Overcoming Cancer Drug Resistance.
    Hu T; Gong H; Xu J; Huang Y; Wu F; He Z
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation.
    Gu W; Meng F; Haag R; Zhong Z
    J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicines as cancer therapeutics: current status.
    Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
    Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine-mediated cancer stem cell therapy.
    Shen S; Xia JX; Wang J
    Biomaterials; 2016 Jan; 74():1-18. PubMed ID: 26433488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotechnology-based delivery systems to overcome drug resistance in cancer.
    Patel H; Li J; Bo L; Mehta R; Ashby CR; Wang S; Cai W; Chen ZS
    Med Rev (2021); 2024 Feb; 4(1):5-30. PubMed ID: 38515777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can nanomedicines overcome cellular-based anticancer drug resistance?
    Sobot D; Mura S; Couvreur P
    J Mater Chem B; 2016 Aug; 4(30):5078-5100. PubMed ID: 32263505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging Bio-Nano Science and Cancer Nanomedicine.
    Björnmalm M; Thurecht KJ; Michael M; Scott AM; Caruso F
    ACS Nano; 2017 Oct; 11(10):9594-9613. PubMed ID: 28926225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thinking small, doing big: Current success and future trends in drug delivery systems for improving cancer therapy with special focus on liver cancer.
    Limeres MJ; Moretton MA; Bernabeu E; Chiappetta DA; Cuestas ML
    Mater Sci Eng C Mater Biol Appl; 2019 Feb; 95():328-341. PubMed ID: 30573256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.